LHC Group
Market Cap
US$5.9b
Last Updated
2021/02/26 00:16 UTC
Data Sources
Company Financials +
Executive Summary
LHC Group, Inc., a health care provider, specializes in the post-acute continuum of care primarily for Medicare beneficiaries in the United States. More Details
Rewards
Risk Analysis
No risks detected for LHCG from our risk checks.
Snowflake Analysis
Excellent balance sheet with acceptable track record.
Similar Companies
Share Price & News
How has LHC Group's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: LHCG is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: LHCG's weekly volatility (4%) has been stable over the past year.
Market Performance
7 Day Return
-6.9%
LHCG
-1.2%
US Healthcare
-3.2%
US Market
1 Year Return
44.7%
LHCG
25.2%
US Healthcare
38.9%
US Market
Return vs Industry: LHCG exceeded the US Healthcare industry which returned 23% over the past year.
Return vs Market: LHCG exceeded the US Market which returned 37.1% over the past year.
Shareholder returns
LHCG | Industry | Market | |
---|---|---|---|
7 Day | -6.9% | -1.2% | -3.2% |
30 Day | -12.9% | -3.8% | -0.8% |
90 Day | -5.2% | 1.1% | 3.1% |
1 Year | 44.7%44.7% | 26.8%25.2% | 42.0%38.9% |
3 Year | 208.0%208.0% | 37.7%32.0% | 60.6%50.3% |
5 Year | 409.5%409.5% | 76.1%63.0% | 128.0%102.5% |
Long-Term Price Volatility Vs. Market
How volatile is LHC Group's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Is LHC Group, Inc. (NASDAQ:LHCG) Trading At A 45% Discount?3 weeks ago | Simply Wall St
Does LHC Group (NASDAQ:LHCG) Have A Healthy Balance Sheet?1 month ago | Simply Wall St
LHC Group, Inc. (NASDAQ:LHCG) Insiders Have Been SellingValuation
Is LHC Group undervalued compared to its fair value and its price relative to the market?
49.2%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: LHCG ($188.11) is trading below our estimate of fair value ($370.31)
Significantly Below Fair Value: LHCG is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: LHCG is poor value based on its PE Ratio (56.7x) compared to the US Healthcare industry average (26.1x).
PE vs Market: LHCG is poor value based on its PE Ratio (56.7x) compared to the US market (21.7x).
Price to Earnings Growth Ratio
PEG Ratio: LHCG is poor value based on its PEG Ratio (2.3x)
Price to Book Ratio
PB vs Industry: LHCG is overvalued based on its PB Ratio (3.9x) compared to the US Healthcare industry average (3.7x).
Next Steps
Future Growth
How is LHC Group forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?
24.6%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LHCG's forecast earnings growth (24.6% per year) is above the savings rate (2%).
Earnings vs Market: LHCG's earnings (24.6% per year) are forecast to grow faster than the US market (20.3% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: LHCG's revenue (9.3% per year) is forecast to grow slower than the US market (10.4% per year).
High Growth Revenue: LHCG's revenue (9.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: LHCG's Return on Equity is forecast to be low in 3 years time (12.2%).
Next Steps
Past Performance
How has LHC Group performed over the past 5 years?
28.8%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: LHCG has high quality earnings.
Growing Profit Margin: LHCG's current net profit margins (5%) are higher than last year (4.6%).
Past Earnings Growth Analysis
Earnings Trend: LHCG's earnings have grown significantly by 28.8% per year over the past 5 years.
Accelerating Growth: LHCG's earnings growth over the past year (9%) is below its 5-year average (28.8% per year).
Earnings vs Industry: LHCG earnings growth over the past year (9%) underperformed the Healthcare industry 16%.
Return on Equity
High ROE: LHCG's Return on Equity (7.9%) is considered low.
Next Steps
Financial Health
How is LHC Group's financial position?
Financial Position Analysis
Short Term Liabilities: LHCG's short term assets ($655.7M) do not cover its short term liabilities ($662.1M).
Long Term Liabilities: LHCG's short term assets ($655.7M) exceed its long term liabilities ($205.7M).
Debt to Equity History and Analysis
Debt Level: LHCG's debt to equity ratio (1.3%) is considered satisfactory.
Reducing Debt: LHCG's debt to equity ratio has reduced from 25.7% to 1.3% over the past 5 years.
Debt Coverage: LHCG's debt is well covered by operating cash flow (2407.1%).
Interest Coverage: LHCG's interest payments on its debt are well covered by EBIT (24.1x coverage).
Balance Sheet
Next Steps
Dividend
What is LHC Group current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate LHCG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate LHCG's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if LHCG's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if LHCG's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of LHCG's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.1yrs
Average management tenure
CEO
Keith Myers (61 yo)
27.08yrs
Tenure
US$4,660,024
Compensation
Mr. Keith G. Myers has been the Co-Founder, Chairman and Chief Executive Officer of LHC Group, Inc. since 1994 and served as its President since December 31, 2019 until June 2020. Mr. Myers has been Direct...
CEO Compensation Analysis
Compensation vs Market: Keith's total compensation ($USD4.66M) is about average for companies of similar size in the US market ($USD6.11M).
Compensation vs Earnings: Keith's compensation has been consistent with company performance over the past year.
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Co-Founder | 27.08yrs | US$4.66m | 2.93% $ 173.9m | |
President | 0.67yr | US$3.41m | 0.25% $ 14.9m | |
Executive VP & General Counsel | 2.08yrs | US$862.17k | 0.019% $ 1.1m | |
Executive VP and Chief Strategy & Innovation Officer | 2.42yrs | US$1.02m | 0.058% $ 3.4m | |
Consultant & Independent Director | 20.67yrs | US$232.82k | 0.10% $ 6.2m | |
Executive VP | 0.25yr | no data | 0.0037% $ 217.5k | |
Senior VP & Chief Accounting Officer | 0.67yr | no data | 0.0088% $ 523.6k | |
Chief Information Officer | 1.17yrs | no data | no data | |
Executive VP & Chief Administrative Officer | no data | no data | no data | |
Senior VP & Chief Compliance Officer | 8.08yrs | no data | no data | |
Senior VP & Chief Communications Officer | no data | no data | no data | |
Division President of Operations – Acadia Division Home Health | no data | no data | no data |
2.1yrs
Average Tenure
53yo
Average Age
Experienced Management: LHCG's management team is considered experienced (2.1 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Co-Founder | 27.08yrs | US$4.66m | 2.93% $ 173.9m | |
Consultant & Independent Director | 20.67yrs | US$232.82k | 0.10% $ 6.2m | |
Independent Director | 19.58yrs | US$244.82k | 0.096% $ 5.7m | |
Independent Director | 3.25yrs | US$228.32k | 0.021% $ 1.2m | |
Independent Director | 3.25yrs | US$228.32k | 0.18% $ 10.5m | |
Transitional Advisory Council | 1.92yrs | US$164.95k | no data | |
Independent Director | 3.25yrs | US$234.61k | 0.43% $ 25.8m | |
Independent Director | 6.5yrs | US$319.06k | 0.039% $ 2.3m | |
Independent Director | 1.92yrs | US$605.36k | 0.018% $ 1.1m | |
Lead Independent Director | 16.08yrs | US$260.82k | 0.13% $ 7.8m | |
Independent Director | 13.25yrs | US$235.82k | 0.091% $ 5.4m | |
Member of Founder's Advisory Board | 7.17yrs | no data | no data |
6.8yrs
Average Tenure
65.5yo
Average Age
Experienced Board: LHCG's board of directors are considered experienced (6.8 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
LHC Group, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: LHC Group, Inc.
- Ticker: LHCG
- Exchange: NasdaqGS
- Founded: 1994
- Industry: Health Care Services
- Sector: Healthcare
- Market Cap: US$5.943b
- Shares outstanding: 31.59m
- Website: https://www.lhcgroup.com
Number of Employees
Location
- LHC Group, Inc.
- 901 Hugh Wallis Road South
- Lafayette
- Louisiana
- 70508
- United States
Listings
Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
---|---|---|---|---|---|---|
LH6 | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jun 2005 |
LHCG | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | Jun 2005 |
Biography
LHC Group, Inc., a health care provider, specializes in the post-acute continuum of care primarily for Medicare beneficiaries in the United States. The company’s Home Health Services segment offers home nu...
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2021/02/26 00:16 |
End of Day Share Price | 2021/02/25 00:00 |
Earnings | 2020/09/30 |
Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.